First Immunotherapy Approved for Basal Cell Carcinoma

(MedPage Today) -- WASHINGTON--The FDA expanded the approval of the anti-PD-1 antibody cemiplimab (Libtayo) to include certain patients with basal cell carcinoma (BCC), the first immuno-oncology approval for the disease.
The approval applies...